Innovative molecules or medical devices in field of ophthalmology/central nervous system/oncology
Our company has a working capital of over 5.2 Billion USD and we invest over 12.5% of the annual revenue in novel projects (compare to other Chinese companies average of ~2%). The company has 10 subsidiaries (5 of them are GMP certified facilities) which focusing in mainland China with strategic overseas operations. At present, the company has 11 marketed drugs in field of ophthamology, central nervous system, cardiovascular system and digestive system. And our product Conbercept Ophthalmic Injection has been approved by FDA in 2016 to carry out Phase III clinical trails on wet AMD in the U.S. and the current clinical trials are well underway, which further demonstrated our determination to enter the international market.
Key advantages:
Our company is one of the largest Ophthalmic distributors in Mainland China and has been able to position over 10 products within the Basic Health Insurance Catalog to achieve market penetration, getting a largest market share for some drugs than the originator companies or large international pharmaceuticals in the local market. Our company manufactures proprietary novel biologic, drugs with clear differenciation in formulation and medical devices.
We are looking for:
- Innovative molecules or medical devices in field of ophthalmology/central nervous system/oncology.
- Joint venture/acquisition/investment for companies with our target drug/device/Tech; Cooperation/service provider for companies with our target Tech (mainly for novel formulation platforms).
Potential partners: Our partners are research institutes with whom we estabish codevelopment projects in the R&D of new drugs or work as consultants. We also partner with drug/medical device manufacturers that make tech transfer or sell finished dose formulations to us.
